• 18.October 2017 | Company news |

    EPO presents two posters with new data of selected topics at AACR-NCI-EORTC International Conference in Philadelphia

    Poster #A005
    Drug screening in patient-derived xenografts from acute myeloic leukemia and non-Hodgkin's lymphoma shows correlation with chemotherapy resistance in patients
    The poster will be presented in Poster Session A "Animal Models"
    on Saturday October 28, 2017 12:30 - 4:00 pm
    In Hall E, Pennsylvania Convention Center, Poster Board number 5;
    Abstract #270-Go to online version...

    Poster #A006 - (Pdf download 70 MB)
    Preclinical tumor models in humanized mice for translational immuno-oncology research
    The poster will be presented in Poster Session A "Animal Models"
    on Saturday October 28, 2017 12:30 - 4:00 pm
    In Hall E, Pennsylvania Convention Center, Poster Board number 6;
    Abstract # 272 - Go to online version...

  • 27.July 2017 | Company news |

    AAALAC accreditation for EPO

    EPO received the full accreditation of AAALAC International, a non-profit organization, that promotes responsible laboratory work with highest quality, scientific, and ethical standards through an accreditation program. This major achievement enables us to provide our service following the best up to date rules and conditions in a strictly controlled way.

    For more details see newsletter October 2017.

  • 14.May 2017 | Company news |

    EPO joint the AACR Annual Meeting 2017 in Washington, D.C. and presented there three posters with impressive consideration.

    Poster #1697
    Humanized immune-oncology mouse models
    Go to online version...

    Poster #1843
    Intratumoral heterogeneity of renal cancer is related to differences in drug response and development of therapy resistance.
    Go to online version ...

    Poster #4943
    Orthotopic transplantation of pancreatic cancer PDX models increases murine stroma content, but does not influence therapeutic response to standard of care.
    Go to online version ...

  • 10.February 2017 | Company press release |

    Tracking resistance - new tumor models predict treatment response to anticancer drugs in colon carcinomas

    Together with international colleagues scientists from Berlin found new genetic patterns, which help to predict response in colon cancer.

    go to press release

  • November 2016 | Company news |

    EPO successfully participated at the 28th EORTC-NCI-AACR Symposium 2016 in Munich

    EPO presented several posters at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in November 29 during the Preclinical Model -, the Drug Resistance and Modifiers - and the Animal Models Poster Sessions.

    EPO participated with an own booth, where we showed an overview about our activities and met customers and collaborators.

    Please click on the link to view our poster presentations.

    We are looking forward to meeting you there. Connect with us now or at the meeting to say hello! Contact us or email us directly to schedule.

  • April 2016 | Company news | Our co-worker Maria Rivera successfully finished her PhD thesis

    Colorectal cancer patient-derived xenograft (PDX) models as platform for drug screening, molecular and response analysis

    Within the frame of her work a panel of 49 colon cancer xenografts was established and comprehensively characterized for

    - indentity with original patient specimen
    - expression of EpCAM and p53
    - expression of growth factor receptors and their ligands
    - mutational profiling
    - response to classical cytotoxic and targeted drugs

    These models are now available for further biomarker analysis and development of novel therapies.

  • 01.04.2016 | Company news

    EPO presented two posters at the AACR Annual Meeting 2016 in New Orleans

    Analysis of murine stromal components in patient-derived xenograft (PDX) models of pancreatic cancer

    The poster is online and available for download >>>

    Preclinical model of patient-derived tumor xenograft in humanized mice

    The posters is now online and available for download >>>

  • 29.02.2016 | Company news

    EPO presented at 32. German Cancer Congress in Berlin 24.-27. February 2016

    Main focus of the congress was the personalised medicine and updates to frequent and rare cancer diseases. Two invited talks were given by Iduna Fichtner with the topic “PDX models in biomarker research” and by Annika Wulf-Goldenberg with the title “Humanized models for testing immunotherapeutics”. Two out of six presented posters were chosen as Best of Abstracts. Wolfgang Walther presented “Phase I gene therapy trial for nonviral jet-injection gene transfer of the TNF-alpha expressing minimalistic MIDGE vector in melanoma patients” and Maria Stecklum “Development of a functional humanized immune system in mice by transplantation of human hematopoietic stem cells – a model for immuno-oncology”.

    The posters from the DKK are now online and available for download (PDX-colon). Please contact us if you have any questions.

  • 15.02.2016 | Company news

    EPO presented at the EORTC-PAMM Winter Meeting in Antwerp, 9-12. February 2016

    The EPO Team has participated at the annual EORTC-PAMM Winter meeting in Antwerp, Belgium. During this meeting EPO presented the potential and challenges of the patient-derived tumor models (PDX) for translational research. Furthermore, the latest developments of EPO in the establishment of glioblastoma and of B-cell lymphoma PDX models were presented as short talks during the meeting. The respective posters can be viewed or downloaded by this link.>>>
    PAMM (PDX-lymphoma) - (PDX-glioma)

  • 05.01.2016 | Company news

    January 2016 - EPO collaboration with NexusPharma

    EPO starts strategic collaboration with NexusPharma to foster its market position in the USA.
    see press release ...

  • 05.01.2016 | Company news

    January 2016 - Histopatology service at EPO

    EPO announces a comprehensive histopatology service for experimental in vivo studies. The independent department offers custom-oriented necropsies, tissue processing, preparation of sections, any (immuno) histological staining and evaluation.

Newsletter on / off

Newsletter - October 2017:

EPO -October 26-30.2017
AACR-NCI-EORTC International Conference in Philadelphia ...
Read more (link)

EPO received full AAALAC accreditation ...
Read more (link)

Newsletter - September 2017:

EPO offers comprehensive support in the preclinical development of biosimilars ...
Read more (link)

Newsletter - March 2017:

EPO at AACR Annual Meeting 2017 in Washington, D.C.
Read more (link)

Newsletter 4:

EPO has developed a large panel of glioma PDX models. Some of them are growing as orthotopic tumors enabling highly sophisticated studies.
Read more (link)

Newsletter 3:

EPO offers ultrasound imaging for the monitoring of tumor growth.
Read more (link)

Newsletter 2:

EPO has available facilities and device for the use of irradiation in vitro and in vivo.
Read more (link)

Newsletter 1:

Besides expertise for the determination of antitumor efficacy EPO has available special technologies for imaging, radiation, biomarker analysis at protein and molecular level.
Here are some examles (link)

Newsletter - Archiv

2017 © EPO Berlin-Buch GmbH